{"id":"https://openalex.org/W4411288972","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28","title":"Abstract P5-09-28: A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer","display_name":"Abstract P5-09-28: A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer","publication_year":2025,"publication_date":"2025-06-13","ids":{"openalex":"https://openalex.org/W4411288972","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28"},"language":"en","primary_location":{"id":"doi:10.1158/1557-3265.sabcs24-p5-09-28","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073840903","display_name":"Guangdong Qiao","orcid":"https://orcid.org/0000-0002-5298-3411","observed_orcids":["https://orcid.org/0000-0002-5298-3411"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guangdong Qiao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jun Lin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Lin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Haidong Zou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Haidong Zou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101676819","display_name":"Yalun Li","orcid":"https://orcid.org/0000-0002-6977-1626","observed_orcids":["https://orcid.org/0000-0002-6977-1626","https://orcid.org/0009-0001-4939-2784"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yalun Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100733168","display_name":"Zhi Liang","orcid":"https://orcid.org/0000-0002-7531-7729","observed_orcids":["https://orcid.org/0000-0002-7531-7729"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhi Liang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051007241","display_name":"Xingmiao Wang","orcid":"https://orcid.org/0000-0002-3692-7065","observed_orcids":["https://orcid.org/0000-0002-3692-7065"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xingmiao Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Ge Gao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ge Gao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119011488","display_name":"Kun Zhang","orcid":"https://orcid.org/0000-0003-0054-2099","observed_orcids":["https://orcid.org/0000-0003-0054-2099","https://orcid.org/0000-0001-9173-4904"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kun Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081432327","display_name":"Yeqing Zhou","orcid":"https://orcid.org/0000-0001-5395-5386","observed_orcids":["https://orcid.org/0000-0001-5395-5386"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yeqing Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102729389","display_name":"Yidan Wang","orcid":"https://orcid.org/0000-0001-7394-1571","observed_orcids":["https://orcid.org/0000-0001-7394-1571"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yidan Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Song Zhang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Song Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100746529","display_name":"Feng Li","orcid":"https://orcid.org/0000-0002-0062-3385","observed_orcids":["https://orcid.org/0000-0002-0062-3385"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Feng Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112853439","display_name":"Xiang Bi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiang Bi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100338528","display_name":"Xiaohui Li","orcid":"https://orcid.org/0000-0002-0624-8811","observed_orcids":["https://orcid.org/0000-0002-0624-8811"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaohui Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Shengqun Yu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shengqun Yu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100606150","display_name":"Yansheng Li","orcid":"https://orcid.org/0000-0002-3466-2593","observed_orcids":["https://orcid.org/0000-0002-3466-2593"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yansheng Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049099741","display_name":"Chunxin Qin","orcid":"https://orcid.org/0000-0001-7185-7421","observed_orcids":["https://orcid.org/0000-0001-7185-7421"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chunxin Qin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Kai Cheng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kai Cheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"12_Supplement","first_page":"P5","last_page":"09"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6567000150680542,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.6567000150680542,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.2775999903678894,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.047600001096725464,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pyrotinib","display_name":"pyrotinib","score":0.8769999742507935},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/dalpiciclib","display_name":"dalpiciclib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/letrozole","display_name":"letrozole","score":1.0},{"id":"https://openalex.org/keywords/triple-positive-breast-cancer","display_name":"triple-positive breast cancer","score":0.8920000195503235},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.7760000228881836},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.675000011920929},{"id":"https://openalex.org/keywords/aromatase-inhibitors","display_name":"aromatase inhibitors","score":0.7480000257492065},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9350000023841858},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.9229999780654907},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5199999809265137},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6100000143051147},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8566271066665649},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8382877707481384},{"id":"https://openalex.org/C2778812593","wikidata":"https://www.wikidata.org/wiki/Q194974","display_name":"Letrozole","level":5,"score":0.8145827054977417},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.629512369632721},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.625298023223877},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5276573896408081},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4484913945198059},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39476317167282104},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.23884359002113342},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.16349980235099792}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1557-3265.sabcs24-p5-09-28","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-p5-09-28","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4309235575","https://openalex.org/W7130691131","https://openalex.org/W4392764472","https://openalex.org/W4281789965","https://openalex.org/W4379284320","https://openalex.org/W7162544813","https://openalex.org/W4414371216","https://openalex.org/W3132106623","https://openalex.org/W3149904663","https://openalex.org/W4322773917"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Triple-positive":[2],"breast":[3,8,42,89,324,423,545],"cancer":[4,9,90,546],"(TPBC)":[5],"is":[6,25,36,46,82,239,417,436],"a":[7,83,172,412,426],"characterized":[10],"by":[11,161,205],"positive":[12,311,349,432],"expression":[13],"of":[14,22,40,66,103,114,281,310,431,452,472,528,550],"ER,":[15],"PR":[16,196],"and":[17,32,64,71,98,147,202,226,235,264,284,300,330,369,385,398,422,425,457,463,534],"HER2.":[18],"The":[19,213,323,360],"first":[20,110,127],"choice":[21],"neoadjuvant":[23,74,155,262,282,345,354,401,473,529],"treatment":[24,52],"anti-HER2":[26],"targeted":[27],"therapy":[28,75,263,283,355,402],"combined":[29],"with":[30,78,92,199,241,343,373,382,405,477,538],"chemotherapy,":[31],"the":[33,62,126,132,206,217,227,258,274,287,306,331,347,450,551],"pCR":[34],"rate":[35,222,233,290,309,326,336,350,430],"lower":[37],"than":[38],"that":[39,87],"HR-/HER2+":[41],"cancer.":[43],"Therefore,":[44],"it":[45],"still":[47],"necessary":[48],"to":[49,60,105,134,164,183,248,419,438,444],"explore":[50,61],"new":[51],"models":[53],"for":[54,208,255,337,475,536],"TPBC":[55,97,410],"patients.":[56],"This":[57,81,237],"study":[58,86,238,527],"aims":[59],"efficacy":[63,462],"safety":[65],"pyrotinib":[67,115,453,530],"plus":[68,121,395,454,531],"trastuzumab,":[69,396,455,532],"dalpiciclib,":[70,397,456,533],"letrozole":[72,148,399,458,535],"as":[73,154,400],"in":[76,125,131,376,403],"patients":[77,91,109,170,191,252,260,267,276,319,380,404,476,537],"TPBC.":[79,482],"Methods:":[80],"single-arm,":[84],"open-label":[85],"enrolled":[88],"early":[93,406,478,541],"or":[94,389,407,479,542],"locally":[95,408,480,543],"advanced":[96,409,481,544],"an":[99,185,468],"ECOG":[100],"performance":[101],"status":[102],"0":[104],"1.":[106],"After":[107],"enrollment,":[108],"received":[111],"2":[112,178],"cycles":[113,188,210,280],"(320":[116],"mg":[117,142,150],"po":[118,143,151],"qd,":[119,144,152],"d1-28)":[120],"trastuzumab":[122,201],"(8":[123],"mg/kg":[124,130],"cycle,":[128],"6":[129,279],"second":[133],"eighth":[135],"cycles,":[136,179],"intravenous":[137],"drip,":[138],"q3w),":[139],"dalpiciclib":[140],"(150":[141],"d1-21,":[145],"q4w)":[146,153],"(2.5":[149],"therapy,":[156,346],"Tumour":[157],"response":[158,175,221,232,289],"was":[159,216,292,314,327,339,351],"assessed":[160,254],"investigators":[162],"according":[163],"RECIST":[165],"1.1":[166],"using":[167],"MRI,":[168],"If":[169],"achieved":[171],"confirmed":[173],"partial":[174],"(PR)":[176],"after":[177,353],"they":[180],"would":[181],"continue":[182],"receive":[184],"additional":[186],"4":[187,209,388],"until":[189,211],"surgery;":[190],"who":[192,277],"did":[193],"not":[194],"achieve":[195],"were":[197,230,253,269,302,320,365],"treated":[198],"pyrotinib,":[200],"chemotherapy":[203,474],"selected":[204],"doctor":[207],"surgery.":[212],"primary":[214],"endpoint":[215],"total":[218],"pathological":[219],"complete":[220,307,428],"(tpCR:":[223],"ypT0/is,":[224],"ypN0),":[225],"secondary":[228],"endpoints":[229],"objective":[231],"(ORR)":[234,291],"safety.":[236],"registered":[240],"ClinicalTrials.gov":[242],"(NCT05800756).":[243],"Results:":[244],"From":[245],"August":[246],"2022":[247],"June":[249],"2024,":[250],"30":[251],"eligibility,":[256],"Among":[257,273],"20":[259,275],"completed":[261,278],"surgery,":[265,286],"17":[266],"(85.00%)":[268],"immunohistochemical":[270],"HER2":[271],"3+.":[272],"underwent":[285],"overall":[288],"100%":[293],"(20/20).":[294],"Postoperative":[295],"MP":[296],"grading":[297],"evaluation:":[298],"tpCR":[299],"bpCR":[301],"both":[303],"20%":[304],"(4/20),":[305],"remission":[308,429],"lymph":[312,333,433,441],"nodes":[313],"13/19":[315],"(68.42%);":[316],"RCB":[317],"(0-\u2160)":[318],"7/20":[321],"(35.00%).":[322],"conservation":[325],"30.00%":[328],"(6/20),":[329],"sentinel":[332,440],"node":[334,442],"biopsy":[335,443],"downstaging":[338,420,439],"35.71%":[340],"(5/14).":[341],"Compared":[342],"before":[344],"Ki67":[348],"reduced":[352],"(41.67\u00b118.48%":[356],"vs":[357],"19.67\u00b121.89%,":[358],"p=0.003).":[359],"most":[361],"common":[362],"adverse":[363,391],"events":[364],"diarrhea,":[366],"oral":[367],"mucositis,":[368],"decreased":[370],"neutrophil":[371],"counts,":[372],"diarrhea":[374],"occurring":[375],"95.00%":[377],"(19/20),":[378],"10":[379],"(50%)":[381],"grade":[383,387],"\u22653,":[384],"no":[386],"higher":[390],"events.":[392],"Conclusion:":[393],"Pyrotinib":[394],"has":[411,459],"high":[413,427],"ORR":[414],"rate,":[415],"which":[416,435,465],"conducive":[418,437],"surgery":[421],"conservation,":[424],"nodes,":[434],"preserve":[445],"axillary":[446],"function.":[447],"In":[448],"conclusion,":[449],"combination":[451],"demonstrated":[460],"good":[461],"safety,":[464],"may":[466],"be":[467],"alternative":[469],"option":[470],"instead":[471],"Citation":[483],"Format:":[484],"Guangdong":[485],"Qiao,":[486],"Jun":[487],"Lin,":[488],"Haidong":[489],"Zou,":[490],"Yalun":[491],"Li,":[492,508,512,516],"Zhi":[493],"Liang,":[494],"Xingmiao":[495],"Wang,":[496,504],"Ge":[497],"Gao,":[498],"Kun":[499],"Zhang,":[500,506],"Yeqing":[501],"Zhou,":[502],"Yidan":[503],"Song":[505],"Feng":[507],"Xiang":[509],"Bi,":[510],"Xiaohui":[511],"Shengqun":[513],"Yu,":[514],"Yansheng":[515],"Chunxin":[517],"Qin,":[518],"Kai":[519],"Cheng.":[520],"A":[521],"phase":[522],"I,":[523],"prospective":[524],"exploratory":[525],"clinical":[526],"HR-positive,":[539],"HER2-positive":[540],"[abstract].":[547],"In:":[548],"Proceedings":[549],"San":[552,561],"Antonio":[553],"Breast":[554],"Cancer":[555,568],"Symposium":[556],"2024;":[557],"2024":[558],"Dec":[559],"10-13;":[560],"Antonio,":[562],"TX.":[563],"Philadelphia":[564],"(PA):":[565],"AACR;":[566],"Clin":[567],"Res":[569],"2025;31(12":[570],"Suppl):Abstract":[571],"nr":[572],"P5-09-28.":[573]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}